Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance

Similar documents
Impaired Glucose Tolerance, Impaired Fasting Glycaemia and Cardiovascular Risk

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Post-challenge hyperglycaemia is associated with premature death and macrovascular complications

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl

Diabetes Mellitus: A Cardiovascular Disease

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Early diagnosis, early treatment and the new diagnostic criteria of diabetes mellitus

The number of diabetic patients in Japan

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes mellitus is diagnosed and characterized by chronic hyperglycemia. The effects of

The Diabetes Link to Heart Disease

Welcome and Introduction

Diabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?

Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead

Prevalence of impaired glucose tolerance in ischemic Egyptian patients

The Metabolic Syndrome: Is It A Valid Concept? YES

How to Reduce CVD Complications in Diabetes?

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Reducing cardiovascular risk factors in patients with prediabetes

Cardiovascular Complications of Diabetes

From Policemen to Policies: What Is the Future for 2-h Glucose?

Diabetes and the Heart

Categories of abnormal glucose homeostasis

Blood glucose variations and cardiovascular risk in patients with diabetes

2010 ADA Guidelines: 1. Diagnostic Criteria for DM 2. Categories of increased risk of DM. Gerti Tashko, M.D. DM Journal Club 1/21/2010

Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya

The American Diabetes Association estimates

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

Hemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Guidelines on cardiovascular risk assessment and management

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Diabetes Mellitus (DM) - Dr Hiren Patt

Prevalence of Diabetes Mellitus among Non-Bahraini Workers Registered in Primary Health Care in Bahrain

WILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa

Metabolic Syndrome: What s in a name?

Diabetic Dyslipidemia

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Standards of Medical Care in Diabetes 2016

Pre-Diabetes and the Risk for Cardiovascular Disease

Update on CVD and Microvascular Complications in T2D

Clinical Practice Guidelines for Diabetes Management

The Impact of Diabetes Mellitus and Prior Myocardial Infarction on Mortality From All Causes and From Coronary Heart Disease in Men

Master Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden

DIABETES. A growing problem

Diabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: The Chin-Shan Community Cardiovascular Cohort study

The Burden of the Diabetic Heart

Identification of subjects at high risk for cardiovascular disease

American Academy of Insurance Medicine

A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus

SCIENTIFIC STUDY REPORT

Philippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus

Screening and Diagnosis of Diabetes Mellitus in Taiwan

Gestational Diabetes in Resouce. Prof Satyan Rajbhandari (RAJ)

Prevalence, Diagnosis, and Treatment of Impaired Fasting Glucose and Impaired Glucose Tolerance in Nondiabetic U.S. Adults

PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

Cut-Off Fasting Plasma Glucose Level To Determine Impaired Glucose Metabolism In Obesity

Glycemic control a matter of life and death

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

Metabolic Syndrome: Why Should We Look For It?

Although medical advances have curbed

Screening Criteria of Diabetes Mellitus and Impaired Glucose Tolerance of the Japanese Population in a Rural Area of Japan: The Tottori-Kofu Study

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Established Risk Factors for Coronary Heart Disease (CHD)

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Strategies for the prevention of type 2 diabetes and cardiovascular disease

SESSION 3 11 AM 12:30 PM

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

DOI: /jemds/2014/2044 ORIGINAL ARTICLE

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Know Your Number Aggregate Report Single Analysis Compared to National Averages

DIABETES UPDATE. Diabetes Update

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

Downloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018

ORIGINAL INVESTIGATION

Frequency of Dyslipidemia and IHD in IGT Patients

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Correlation between triglyceride level and carotid intima media thickness in patients with type 2 diabetes mellitus

METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS

Diabete: terapia nei pazienti a rischio cardiovascolare

Type 2 Diabetes Mellitus 2011

Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study

Transcription:

CLINICAL PRACTICE Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance John MF. Adam*, Daniel Josten** ABSTRACT The American Diabetes Association has strongly recommended that fasting plasma glucose should be sufficient for establishing diagnosis of diabetes mellitus; while World Health Organization supports to maintain the oral glucose tolerance test. Several epidemiological studies confirmed that postprandial hyperglycemia is a significant predictor for cardiovascular mortality and incidence. Post-challenge hyperglycemia following the oral glucose tolerance test is a condition similar to postprandial hyperglycemia. Isolated post-challenge hyperglycemia is a type of diabetes mellitus with a normal fasting plasma glucose level measured by oral glucose tolerance test. However, the glucose level following 2-hour post-challenge glucose test is > 200 mg/dl. Several long-term studies on population have shown that subjects with isolated postchallenge hyperglycemia have higher risk for cardiovascular events and mortality. Moreover, they also have an equal risk as those who have previously had diabetes mellitus. Therefore, it is suggested that for screening of diabetes mellitus, especially in the elderly population, oral glucose tolerance test should be performed in addition to measuring fasting plasma glucose. Key words: IPH (Isolated Post-challenge Hyperglycemia), and impaired glucose tolerance (IGT) * Diabetes and Lipid Center, Department of Internal Medicine, Faculty of Medicine University of Hasanuddin-Dr. Wahidin Sudirohusodo Hospital, Jalan Perintis Kemerdekaan km. 11, Makasar. Email: johna@indosat.net.id, ** Department of Internal Medicine, Jaury Academic Hospital, Makasar. INTRODUCTION Diagnosis of diabetes mellitus can be established based on 3 methods, i.e.: a). for those who have specific symptoms of diabetes mellitus such as weight loss, polyuria, and polydipsia, a high plasma glucose level of > 200 mg/dl, should be sufficient to establish diagnosis of diabetes mellitus, b). fasting plasma glucose level of > 126 mg/dl, and c). Two hour post-prandial blood glucose level > 200 mg/dl following 75 gram postprandial glucose challenge test in oral glucose tolerance test (OGTT 75 gram glucose). 1 There are two different concepts between American Diabetes Association (ADA) and International Diabetes Federation (IDF) on diagnosis criteria of diabetes mellitus. The American Diabetes Association has recommended that single examination of a fasting plasma glucose level should be adequate for diagnosis of diabetes mellitus, which is easy to perform with lower cost. 2 In contrast, IDF has still strongly recommended to use the OGTT 3 based on rationale that normal fasting plasma glucose level is frequently found in elderly. Howeveer, on OGTT, the glucose level following 2-hour post-challenge glucose test is > 200 mg/dl. In other words, diagnosis of diabetes mellitus is established only based on 2-hour postchallenge glucose level or post-ogtt. By performing OGTT, the glucose level following 2-hour post-challenge glucose test will provide three results, i.e.: normal result if the plasma glucose level is <140 mg/dl, impaired glucose tolerance (IGT) ranged in 140-200 mg/dl, and diabetes mellitus if the plasma glucose level is > 200 mg/dl. If the OGTT is performed following examination of fasting plasma glucose level, then the diagnosis of diabetes mellitus will be established based on fasting plasma glucose level of > 126 mg/dl and 2-hour post-ogtt glucose level of > 200 mg/dl. However, the fasting plasma glucose level can be < 126 mg/dl but the 2-hour post-ogtt glucose level > 200 mg/dl. The last condition has become known as isolated post-challenge hyperglycemia (IPH). The IPH will be discussed further on this paper, particularly related to cardiovascular disease. 171

John MF Adam, et al Acta Med Indones-Indones J Intern Med CLASSIFICATION OF DIABETES MELLITUS AND PLASMA GLUCOSE LEVELS In 1979, The National Diabetes Data Group, Diagnosis and Classification of Diabetes and Other Categories of Glucose Intolerance 4 in USA introduced the new classification of diabetes mellitus for the first time. Afterward, it was widely brought in by the WHO Expert Committee on Diabetes Mellitus 5 in 1980. The classification introduced a category of hyperglycemia state which is not normal but it has not met the criteria of diabetes mellitus. Such category was known as impaired glucose tolerance or toleransi glukosa terganggu (TGT) when it is translated into Indonesian term. Impaired glucose tolerance is defined as 2-hours post-challenge plasma glucose level of 140-200 mg/dl on OGTT. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 6 in USA made other new diagnosis criteria and classification on diabetes mellitus in 1997, which was also adopted by the WHO 7 in 1999. (Table 1) An important thing to distinguish it with a previous definition of normal glucose was a new concept on fasting plasma glucose level, i.e. the impaired fasting glucose (IFG), which has similarity with OGTT. Impaired fasting glucose is defined as fasting plasma glucose level of 110-126 mg/ dl, which has been translated into Indonesian term as glukosa puasa terganggu (GPT) by the Consensus of Diabetes Mellitus Management on 2002. 8 As it progresses, the American Diabetes Association 2 changed the IFG definition again in 2003, from previously 110-125 mg/dl to 100-125 mg/dl. (Table 2) Both IFG and IGT have normal values in HbA1C measurement. This demonstrates that both conditions are not considered as diabetes mellitus. Although both IFG and IGT have different etiology and pathogenesis, however, they become risk factors for potential diabetes mellitus in the future. 9 When an individual has both IFG and IGT detected at the same time, then the risk of diabetes mellitus will be higher compared to an individual who only has IFG or IGT. Some epidemiological studies demonstrate that the number of subjects with IGT is higher than IFG. Therefore, IGT developed more frequently to be diabetes mellitus than IFG. 1,10,11 Recently, both IFG and IGT are known as pre-diabetes, the general name used worldwide. In addition to their potential risk to the forthcoming diabetes mellitus, both have also been known as risk factors for cardiovascular disease. Nevertheless, IGT has stronger correlation to cardiovascular disease compared to IFG. 12 172

Vol 40 Number 3 July 2008 Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance THE PREVALENCE OF ISOLATED POST-CHALLENGE HYPERGLYCEMIA When the fasting plasma glucose test and OGTT are performed, most of patients with diabetes mellitus will be diagnosed by fasting plasma glucose level of >126 mg/dl and OGTT > 200 mg/dl. The DECODE study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) conducted in Europe, involving 7680 male and 9251 female subjects aged between 30 89 years-old, has classified diabetes mellitus based on 3 criteria: a). There was only 28.0% subjects with fasting plasma glucose and OGTT criteria, b). while there were 40.0% subjects who merely met the criteria of fasting plasma glucose, c). while in 31.0% of subjects, they were detected with merely OGTT criteria or IPH criteria. 13 (Figure 1) A similar study in Asia known as The Diabetes Epidemiology Collaborative Analysis of Diagnostic Criteria in Asia (DECODA) 14 involving 6817 subjects found that 43% patients with diabetes mellitus were newly detected. Of such number, 43% subjects were diagnosed as IPH. The NHANES (National Health and Nutrition Examination Survey) III study in the USA found that among the newly diagnosed patients with diabetes mellitus aged 40 74 years-old, 44.0% diagnoses were established based on fasting plasma glucose and OGTT criteria, only 14% were diagnosed based on fasting plasma glucose criteria and the remained 41.0% were based on 2-hours OGTT criteria. 15 Barret-Connor reported that from 1858 male and female participants aged 50-89 years-old in the The Rancho Bernardo Study, they found 258 (13.88%) subjects of new diabetic patients and 154 (59.7%) of them were IPH. 16 CLINICAL IMPLICATION OF ISOLATED POST- CHALLENGE HYPERGLYCEMIA It has been known since earlier that the main cause of death in patients with diabetes mellitus is due to cardiovascular disease, and approximately 80% cases are caused by coronary artery disease. Compared to the normal population, some studies have demonstrated that patients with diabetes mellitus have two to three time higher risks of coronary artery disease. 17 The major cause of high cardiovascular mortality in patients with diabetes mellitus, particularly in DM type 2, is hyperglycemia, in addition to other risk factors such as obesity, hypertension, and dyslipidemia. Frequently these factors are detected earlier before the diagnosis of diabetes mellitus itself. A study by Haffner et al 18 in 1998 has demonstrated that diabetic patients without coronary artery disease have an equal risk of developing acute myocardium infarction in the future compared to patients who have had coronary artery disease previously. Therefore, today, in the context of preventing coronary artery disease, patients with diabetes mellitus are treated equally as those with history of myocardial infarction. (Figure 2) Figure 2. Type 2 diabetes mellitus (DM) and coronary artery disease (CAD). The 7 year incidence of fatal or nonfatal myocardial infarction (MI) is essentially the same in patients who have diabetes without a history of CAD and in patients with CAD who are not diabetic. P < 0,001 for the difference between patients with and without MI in both group. Haffner SM, et al. 18 Figure 1. Different diagnosis of DM in asymptomatic subjects. FPG = fasting plasma glucose; 2 hr PG = 2 hr post-challenge glucose. Sourced: The DECODE Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. 14 Several studies have confirmed that IPH is a significant predictor for developing cardiovascular events in the future. In Honolulu Heart Program, which involved 8006 male participants aged 45-70 years old; found that post-challenge glucose level was strongly associated with cardiovascular events. 19 Hence, in Funagata Study that compared IFG and IGT subjects, concluded that IGT has the role as a risk factor for cardiovascular events rather than IFG. 20 The Rancho 173

John MF Adam, et al Acta Med Indones-Indones J Intern Med Bernardo Study in the USA that has monitored patients with IPH for 7 years, found that the risk of cardiovascular disease is significantly higher than non-diabetic patients. Cardiovascular disease obviously has independent correlation with age, hypertension, central obesity, smoking, HDL cholesterol, and triglycerides. 9 Similar findings have been reported by the DECODE study in Europe, which indicated that 2 hour postchallenge glucose level in OGTT has strongly been correlated to morbidity and mortality of cardiovascular disease. The study has also shown that mortality risk of patients with high level of fasting plasma glucose will only be apparent if it is accompanied by an increase of 2-hour post-ogtt glucose level. 13 MANAGEMENT Management of IPH is similar to the management of patients with the type 2 diabetes mellitus. The consensus of American Diabetes Association and European Association for the Study of Diabetes in 2006 21 has confirmed that life style modification and metformin as the first step for management of the type 2 diabetes mellitus. Metformin was recommended as the first-line drug because it decreases plasma glucose level, either in fasting or after meal condition. Moreover, it does not cause hypoglycemia or obesity, and it also has anti-aterogemic effect. Some precautions in taking metformin treatment: 1. Considering that most of IPH patients are elderly, the kidney and liver functions should be concerned before commencing metformin treatment 2. Since most of IPH patients only have mild hyperglycemia, metformin dose should be adjusted; starting with a low dose, such as 500 mg/day 3. The IPH patients are mostly elderly and consequently, the risk of cardiovascular events is more common, such hypertension and dyslipidemia. Management for both risk factors is similar to other diabetic patients 4. Aspirin should be given, except it is contraindicated 5. It is possible that IPH patients have already had history of cardiovascular disease such as postischemic stroke or coronary artery disease, which means more intensive treatment for hypertension or dyslipidemia is necessary. ACKNOWLEDGEMENT An acknowledgement is dedicated to Ms. Lili Linggar with her assistance to provide typing of this article. REFERENCES 1. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care. 1997;20:1183 97. 2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care. 2003;26:3160-76. 3. Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539 55. 4. National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-57. 5. World Health Organization. Diabetes mellitus: Report of a WHO Study Group. Technical Report Series 646, World Health Organization, Geneva-Switzerland, 1980. 6. The Expert Committee on the Diagnosis and Classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care. 1997;20:1183-97. 7. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva Switzerland, 1999. 8. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia, Perkumulan Endokrinologi Indonesia, 2006. 9. American Diabetes Association. Clinical practice recommendations. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;S5 S10. 10. Barret-Connor E. Factors associated with the distribution of fasting plasma glucose in an adult community. Am J Epidemiol. 1980;112:518-23. 11. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385-394. 12. Jackson RA. Mechanisms of age-related glucose intolerance. Diabetes Care. 1990;13:9-19. 13. The DECODE Study Group. Age - and sex-specific prevalence of diabetes and impaired glucose regulation in 13 European Cohorts. Diabetes Care. 2003;26:61-9. 14. The DECODE Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Re-analysis of European epidemiological data. BMJ. 1998; 317: 371-5. 15. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular risk profiles. Result from the third National Health and Nutrition Examination Survey. Diabetes Care. 2000; 23:176-80. 16. Barret-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care. 1998; 21(8):1236-9. 17. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937 42. 18. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subject with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229 34. 19. Donahue R, Abbott R, Reed D, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36(6):689-92. 174

Vol 40 Number 3 July 2008 Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance 20. Tominaga M, Eguchi H, Manaka H, Igarishi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but nor impaired fasting glucose. Diab Care. 1999;22:920-4. 21. Nathan DM, Buse JB, Davidson MB, Henine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diab Care. 2006;29:1963 72. 175